SCHEMBL19974725

SCHEMBL19974725

CC(NCC1CCN(C(=O)O)CC1)C(O)C(=O)NCC1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 3/20 0.39
GAA P10253 1/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP2D6 P10635 1/20 0.38
EPHX1 P07099 3/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TDP1 Q9NUW8 2/20 0.36
EPHX2 P34913 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
LIPE Q05469 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP9 P14780 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974866 0.94 EPHX2 (0.37) MEN1KMT2AKDM4EEPHX1TDP1
SCHEMBL19975350 0.87 EPHX1 (0.45) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL19975153 0.87 EPHX1 (0.45) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL19975303 0.85 MEN1 (0.37) MEN1KMT2AALDH1A1GAAKDM4E
SCHEMBL21176375 0.84 KDM4E (0.50) MEN1KMT2AALDH1A1KDM4EEPHX1
SCHEMBL28767036 0.83 EPHX2 (0.40) MEN1KMT2AKDM4EEPHX1EPHX2
SCHEMBL28767035 0.83 EPHX2 (0.40) MEN1KMT2AKDM4EEPHX1EPHX2
SCHEMBL19974829 0.81 TDP1 (0.40) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL19975112 0.78 MEN1 (0.36) MEN1KMT2AALDH1A1GAAKDM4E
SCHEMBL21176252 0.77 KDM4E (0.53) KMT2AALDH1A1KDM4EEPHX1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C MEN1 4331/4885KMT2A 4031/4885ALDH1A1 2271/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C MEN1 4331/4885KMT2A 4031/4885ALDH1A1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.